NASDAQ:MDXG MiMedx Group (MDXG) Stock Price, News & Analysis $3.06 -0.06 (-1.77%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$3.02 -0.03 (-0.98%) As of 11/20/2026 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About MiMedx Group Stock (NASDAQ:MDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MiMedx Group alerts:Sign Up Key Stats Today's Range$3.03▼$3.1450-Day Range$3.06▼$4.9352-Week Range$3.03▼$7.45Volume2.12 million shsAverage Volume1.73 million shsMarket Capitalization$445.80 millionP/E RatioN/ADividend YieldN/APrice Target$8.14Consensus RatingModerate Buy Company Overview MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company’s products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets. Joseph Capper has served as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More MiMedx Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreMDXG MarketRank™: 2.569045282485 of 5 starsMiMedx Group scored higher than 51% of companies evaluated by MarketBeat, and ranked 461st out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMiMedx Group has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMiMedx Group has a consensus price target of $8.14, representing about 166.5% upside from its current price of $3.06.Amount of Analyst CoverageMiMedx Group has only been the subject of 3 research reports in the past 90 days.Read more about MiMedx Group's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MiMedx Group are expected to grow in the coming year, from ($0.08) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is -23.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is -23.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMiMedx Group has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.30% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 4.35.Change versus previous monthShort interest in MiMedx Group has recently decreased by 3.20%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.18 News SentimentMiMedx Group has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MiMedx Group this week, compared to 3 articles on an average week.Search Interest4 people have searched for MDXG on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have not sold or bought any company stock.Percentage Held by Insiders2.50% of the stock of MiMedx Group is held by insiders.Percentage Held by Institutions79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MiMedx Group's insider trading history. Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDXG Stock News HeadlinesMiMedx Group (NASDAQ:MDXG) Downgraded by Wall Street Zen to "Sell"November 21 at 1:18 AM | americanbankingnews.comMiMedx Group (NASDAQ:MDXG) Stock Rating Reaffirmed as Overweight by Cantor FitzgeraldNovember 19 at 2:54 AM | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 22 at 1:00 AM | Base Camp Trading (Ad)MIMEDX to Participate in Upcoming Investor ConferencesNovember 6, 2026 | globenewswire.comMiMedx (MDXG) Stock Slips As Q3 Earnings Leave Profit QuestionsOctober 31, 2026 | finance.yahoo.comMiMedx Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 28, 2026 | marketscreener.comMMiMedx outlines $250M-$260M 2026 net sales as it targets >20% adjusted EBITDA margin with SanaraOctober 28, 2026 | seekingalpha.comMIMEDX announces $25M patent license agreementOctober 28, 2026 | msn.comSee More Headlines MDXG Stock Analysis - Frequently Asked Questions How have MDXG shares performed this year? MiMedx Group's stock was trading at $6.77 at the beginning of the year. Since then, MDXG stock has decreased by 54.9% and is now trading at $3.0550. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc (NASDAQ:MDXG) announced its quarterly earnings data on Wednesday, October, 28th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.00 by $0.01. The firm earned $62.28 million during the quarter, compared to the consensus estimate of $68.56 million. MiMedx Group had a positive trailing twelve-month return on equity of 2.39% and a negative net margin of 6.32%. Read the conference call transcript. Who are MiMedx Group's major shareholders? MiMedx Group's top institutional investors include Nantahala Capital Management LLC (4.74%), State Street Corp (3.02%), American Century Companies Inc. (1.30%) and Goldman Sachs Group Inc. (1.24%). Insiders that own company stock include Joseph H Capper, William Frank Iv Hulse, Ricci S Whitlow and Kimberly Maersk-Moller. View institutional ownership trends. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiMedx Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiMedx Group investors own include Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), NVIDIA (NVDA), Bristol Myers Squibb (BMY) and OPKO Health (OPK). Company Calendar Last Earnings10/28/2026Today11/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, MDXG's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MDXG CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees808Year Founded2008Price Target and Rating Average Price Target for MiMedx Group$8.14 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+166.5%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$48.58 million Net Margins-6.32% Pretax Margin-7.37% Return on Equity2.39% Return on Assets1.85% Debt Debt-to-Equity RatioN/A Current Ratio4.35 Quick Ratio3.84 Sales & Book Value Annual Sales$303.73 million Price / Sales1.47 Cash Flow$0.55 per share Price / Cash Flow5.51 Book Value$1.45 per share Price / Book2.11Miscellaneous Outstanding Shares145,926,000Free Float142,278,000Market Cap$445.80 million OptionableOptionable Beta1.17 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:MDXG) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredGold Miners Post Record Cash Flows as AI Stocks WobbleGold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredNoah’s Ark found?Scientists may have discovered Noah's Ark buried under a mountain in eastern Turkey, just two miles from the I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share MiMedx Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.